A Study of a Side Effects and Resource Navigation Program for People With Cancer

Official record

Identifier

NCT07646847

Recruiting locations

country

United States

Interventions studied

Immunotherapy CARE Program

Lead sponsor

Memorial Sloan Kettering Cancer Center

Target enrolment

200 participants

Study type

INTERVENTIONAL

Phase

Not applicable

Status

Recruiting

First posted

Jun 15, 2026

Last updated on the registry

Jul 31, 2026

Age

18 Years

Sex

ALL

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

* Documentation of Disease

  o Patient must have pathologically confirmed kidney, bladder, breast, or lung cancer (per EMR)
* Prior Treatment

  o Within three weeks (+/- 3 weeks) of starting PD-1 or PD(L)-1 immune checkpoint inhibitors as monotherapy or in combination with other therapies (per EMR)
* Age ≥ 18 (per EMR)
* Not Pregnant and Not Nursing (per self-report)
* At least one essential need (e.g., food, transportation, housing), as determined by the ICCAN Essential Needs Screener (per self-report)
* Lives in New York metro area, including Long Island, New Jersey, Connecticut, and Pennsylvania (per self-report)
* Can speak English or Spanish (per self-report)
* Has no significant psychiatric disturbance sufficient to preclude completion of the assessment measures, interview, or informed consent (i.e., acute psychiatric symptoms which require individual treatment) (per EMR, patient's care team, or study team)
* Has no presence of cognitive impairment disorder (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection (per EMR, patient's care team, or study team)